Huisheng (HS) ranked second in efficacy [OR = 1.34, 95% CI: 1.10–1.61], with its emodin component suppressing NSCLC proliferation via NF-κB pathway inhibition. This evidence concerns the gene NFKB1 and non-small cell lung carcinoma.